The FDA approved aclidinium bromide (Tudorza Pressair) 400 μg twice daily, a multi dose dry powder inhaler, as maintenance therapy for chronic obstructive pulmonary disease (COPD). This drug is not used as a rescue inhaler, but acts as a long acting muscarinic agonist. Common side effects include headache, nasopharyngitis and cough while serious adverse side effects include paradoxical bronchospasm, new or worsened urinary retention, or new or worsened acute narrow angle-glaucoma. What is the current treatment regimen for COPD?